3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
6
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
63
Carcinoma, Hepatocellular
55
Lung Neoplasms
32
Breast Neoplasms
29
Small Cell Lung Carcinoma
23
Neoplasms
21
Triple Negative Breast Neoplasms
18
Neoplasm Metastasis
17
Urinary Bladder Neoplasms
15
Carcinoma, Transitional Cell
15
Melanoma
14
Colorectal Neoplasms
14
Glioblastoma
10
Prostatic Neoplasms
9
Ovarian Neoplasms
9
Head and Neck Neoplasms
9
Recurrence
8
Liver Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Renal Cell
8
Mesothelioma, Malignant
7
Uterine Cervical Neoplasms
6
Sarcoma
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Rectal Neoplasms
5
Kidney Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Squamous Cell
5
Pancreatic Neoplasms
4
Interventions
Cyclophosphamide
240
Rituximab
187
fludarabine phosphate
129
Etoposide
110
Peripheral Blood Stem Cell Transplantation
108
Mycophenolic Acid
94
Filgrastim
91
Melphalan
90
Whole-Body Irradiation
88
fludarabine
80
Busulfan
80
Tacrolimus
71
Cytarabine
66
Cyclosporine
66
Radiotherapy
62
Methotrexate
53
Antilymphocyte Serum
53
Granulocyte Colony-Stimulating Factor
51
Vincristine
49
Carmustine
48
Doxorubicin
41
Prednisone
37
Thiotepa
33
Bendamustine Hydrochloride
32
Bortezomib
30
Methylprednisolone
29
Dexamethasone
28
Stem Cell Transplantation
27
thymoglobulin
26
ibritumomab tiuxetan
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Non-Hodgkin
×
atezolizumab
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled